Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237689 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Glucocorticoids on Cognition in HIV-infected Women
A Early Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 136
- Enrollment target
NCT03237689: Completed Early Phase 1 study, sponsored by Johns Hopkins University.
NCT03237689 is a Early Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 136 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (157% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03237689, a Early Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
Despite treatment with antiretroviral therapy, women living with HIV continue to experience cognitive impairment. Psychological risk factors, including stress, impair cognition more in HIV-infected women than HIV-uninfected women. This study plans to examine a novel intervention for cognitive dysfunction that targets the mechanisms by which stress negatively affects cognitive functioning.
Primary Outcome
a 12-item list-learning task across 3 trials used to measure total learning. Outcome=total learning across trials (range 0-36). Neuropsychological measures are normed on populations and therefore the clinical significance of a score can be assessed in relation to expected levels of performance.
Interventions
- DRUG Hydrocortisone
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2023-09-08 |
| Phase | Early Phase 1 |
What the finished NCT03237689 record still lists
NCT03237689 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (157% higher).
The record links to 0 conditions, and to 2 interventions - of which Hydrocortisone is the first listed.
NCT03237689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03237689 about?
NCT03237689 is a clinical study titled "Effects of Glucocorticoids on Cognition in HIV-infected Women". Despite treatment with antiretroviral therapy, women living with HIV continue to experience cognitive impairment. Psychological risk factors, including stress, impair cognition more in HIV-infected women than HIV-uninfected women. This study plans to examine a novel intervention for cognitive dysfun...
What is the current status of trial NCT03237689?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 136 participants. The study started on 2017-11-20. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT03237689?
The interventions under investigation include: Hydrocortisone (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03237689?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03237689's enrollment target sits among peer trials
136 125th of 2000 higher than 1,874 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI